Scinai Expands CDMO Footprint with $3.1M in Committed Orders
Event summary
- Scinai reported $3.1M in committed CDMO orders as of August 16, 2026, with $2.1M invoiced.
- First-half 2026 revenues increased to $949K, up from $773K in 2025, driven by Yavne acquisition.
- Gross loss widened to $2.4M due to expanded CDMO cost base following Yavne integration.
- Received $650K in cash payments for expanded U.S. clinical manufacturing program.
- Net income of $1.6M, including $6.4M bargain purchase gain from Recipharm Israel acquisition.
The big picture
Scinai's focus on expanding its CDMO business reflects a broader industry trend of biopharmaceutical companies seeking flexible, outsourced manufacturing solutions. The strategic shift toward commercial execution and facility utilization comes as the company integrates its recent acquisition of Recipharm Israel, positioning itself as a key player in the contract manufacturing space. The $6.4M bargain purchase gain underscores the financial benefits of this acquisition, but the company's ability to sustain operational profitability remains a critical watchpoint.
What we're watching
- Commercial Execution
- Whether Scinai can convert its $5M CDMO revenue target into actual results by year-end.
- Facility Utilization
- The pace at which Jerusalem and Yavne facilities reach optimal operational capacity.
- Therapeutic Development
- How progress on PC111 and NanoAbs platforms will impact long-term strategic positioning.
Related topics